Xanthine oxidoreductase (XOR) may exert an important, but poorly defined, role in the pathogenesis of breast cancer (BC). Loss of XOR expression was linked to aggressive BC, and recent clinical observations have suggested that decreasing XOR may be functionally linked to BC aggressiveness. The goal of the present investigation was to determine whether the decreased XOR observed in clinically aggressive BC was an intrinsic property of highly invasive mammary epithelial cells (MEC). Expression of XOR was investigated using HC11 mouse MEC, HB4a and MCF-10A normal human MEC, and several human mammary tumor cells including MCF-7 and MDA-MB-231. Consistent with clinical observations, data shown here revealed high levels of XOR in normal HC11 and MCF-10A cells that was markedly reduced in highly invasive mammary tumor cells. The contribution of XOR to tumor cell migration in vitro was investigated using MDA-MB-231 and MCF-7 cells and clonally selected derivatives of HC11 that exhibit either weak or strong migration in vitro. We observed that over-expression of an XOR cDNA in MDA-MB-231 and in HC11-C24, both possessing weak XOR expression and high migratory capacity, inhibited their migration in vitro. Conversely, pharmacological inhibition of XOR in MCF-7 and HC11-C4, both possessing high XOR expression and weak migratory capacity, stimulated their migration in vitro. Further experiments suggested that XOR derived ROS mediated this effect and also modulated COX-2 and MMP levels and function. These data demonstrate a functional link between XOR expression and MEC migration and suggest a potential role for XOR in suppressing BC pathogenesis.
X
anthine oxidoreductase (XOR) may exert an important, but poorly defined, role in the pathogenesis of breast cancer (BC). Loss of XOR activity has been linked to aggressive hepatic, renal, gastric, and mammary cancer [Linder et al., 2005 [Linder et al., , 2006 . In both mouse models of mammary carcinogenesis and in human BC patients decreasing mammary epithelial cell (MEC) XOR was associated with and/or predictive of poor clinical outcome and the degree of BC aggressiveness [Lewin et al., 1957; Cook et al., 1997; Shan et al., 2002; Linder et al., 2005] . Patients without evident epithelial XOR expression had the most aggressive BC and had 2.5-fold increased risk of recurrence compared with patients expressing normal or modestly reduced XOR [Linder et al., 2005] . A similar decline in serum XOR has been linked to aggressive stage in BC patients [Alsabti, 1980] . These data raise the possibility that downregulation of XOR may be functionally linked to aggressive BC.
Although it is poorly expressed in virgin mammary glands , XOR is an abundant milk protein and it is highly expressed in mammary tissue during pregnancy and lactation [Linder et al., 1999; Garattini et al., 2003; Anderson et al., 2007] where it plays an important functional role in lactation and differentiation of MEC [Kurosaki et al., 1996; Linder et al., 1999; McManaman et al., 1999 McManaman et al., , 2000 McManaman et al., , 2002 Seymour et al., 2006; Anderson et al., 2007] . Heterozygous XOR knockout mice (XORþ/À) exhibit disrupted formation of the milk fat globule [Vorbach et al., 2002] , and recent data demonstrate that XOR forms a sulphydrylbond-dependent complex with butyrophilin (Btn) and adipophilin (ADPH) in the milk fat globule membrane. This functional interaction between XOR, Btn, and ADPH appears to be essential for the formation of the milk fat globule during lactation [McManaman et al., 2002; Anderson et al., 2007] .
While XOR may contribute to alcohol induced BC pathogenesis and carcinogenesis Maciel et al., 2004; Castro et al., 2008] , the potential for XOR down-regulation to contribute to BC aggressiveness is unknown. XOR is a member of the molybdoflavo-proteins that catalyzes the formation of uric acid from xanthine and hypoxanthine. During purine oxidation XOR is a source of reactive oxygen species (ROS) that have been implicated in numerous human diseases [Garattini et al., 2003] . Both H 2 O 2 and O À: 2 are ROS produced from XOR following conversion of D-form XOR to O-form XOR, and in most cells expressing XOR approximately 40% of the native enzyme is in O-form [Garattini et al., 2003] . XOR also possesses two potentially relevant catalytic functions in addition to purine oxidation. Recent evidence indicates that XOR can convert nitrites into nitric oxide (NO), contributing to the formation of peroxynitrite and perhaps other reactive nitrogen species (RNS) [Godber et al., 2000; Li et al., 2004; Millar, 2004] . XOR is also a highly efficient ROS generating NADH oxidase [Sanders et al., 1997; Maia et al., 2005 Maia et al., , 2007 , and this catalytic function cannot be inhibited by the substrate analogs allopurinol or oxypurinol. Furthermore, uric acid, the product of purine oxidation by XOR, is itself a well-recognized scavenger of peroxynitrite and hydroxyl radical [Becker, 1993; Hooper et al., 2000; Kean et al., 2000] . As a source of intracellular ROS, RNS, or uric acid XOR could potentially regulate many aspects of MEC function or signaling that could modulate BC pathogenesis, including regulation of cyclooxygenase-2 (COX-2) [Ohtsubo et al., 2004] , hypoxia inducible factor-1 (HIF-1) [Griguer et al., 2006] , peroxisome proliferator activator receptor-(PPAR-) [Cheung et al., 2007] , NF-B [Matuschak et al., 2004] , or other unknown factors.
ROS may have widely divergent effects on cancer cell migration and cancer pathogenesis. On the one hand ROS have been reported to stimulate cancer cell or smooth muscle cell migration by activating protein kinase-C (PKC) and the ERK MAP Kinase [Lo et al., 2005; Wu et al., 2006] , and this may be responsible for tumor progression in certain tumors [Storz, 2005; Wu, 2006] . However, as noted elsewhere ''the mechanism by which cells respond to reactive oxygen species depends on the molecular background of cell and tissues, the location of ROS production, and the concentration of individual ROS species'' [Storz, 2005] . Indeed, elevation of ROS levels in some cancer cells appeared to inhibit migratory activity, while scavenging of ROS stimulated migratory activity [Shim et al., 2006] . As an intracellular source of ROS, XOR may be anticipated to affect migratory activity of cancer cells, although it is uncertain how this effect would unfold.
The goal of the present investigation was to determine whether the decreased XOR observed in clinically aggressive BC was an intrinsic property of highly invasive mammary cancer cells. Data shown here have, for the first time, demonstrated vigorous XOR expression in normal or weakly invasive MEC that is lost in highly invasive MEC. Furthermore, over-expression of recombinant XOR cDNA in highly invasive MEC inhibits their migration in vitro, whereas pharmacological inhibition of XOR in MEC possessing high XOR activity and weak migratory activity induces their migration in vitro. Present experiments indicate that XOR derived ROS as well as modulation of COX-2 levels and the levels and function of matrix metaloproteases-1 and -3 (MMP-1, -3) may be involved in the suppressive effect of XOR on MEC migration. 
MATERIALS AND METHODS

REAGENTS
CELLS AND CULTURE CONDITIONS
HC11 mouse MEC were grown in RPMI 1640 containing 2 mM Lglutamine, 2 g/L sodium bicarbonate, pH 7.4, 1X of antibiotic/ antimycotic solution, 5ug/ml insulin, 10ng/ml epidermal growth factor, 10% fetal calf serum [Hynes et al., 1990] . Cells were maintained at 37 o C in 95% air/5% CO 2, fed every 2 days, and split 1:4 when at, or near, confluency. MCF-10A and Hb4a normal human MEC were grown as described [Page et al., 1998 ] with minor modifications as follows. Medium consisted of RPMI 1640 containing 2 mM L-glutamine, 2 g/L sodium bicarbonate, pH 7.4, 1Â of antibiotic/antimycotic solution, 5 g/ml insulin, 5 g/ml hydrocortisone, 100 ng/ml cholera toxin, and 10% fetal calf serum.
Cells were maintained at 37 o C in 95% air/5% CO 2 , fed every 2 days, and split 1:4 when at, or near, confluency. T47D cells were grown in RPMI 1640 containing 2 mM L-glutamine, 2 g/L sodium bicarbonate, pH 7.4, 1Â of antibiotic/antimycotic solution, 5 g/ml insulin, and 10% fetal calf serum. All other cancer cell lines were grown in DMEM (high glucose) containing 2 mM L-glutamine, 2 g/L sodium bicarbonate, pH 7.4, 1Â of antibiotic/antimycotic solution, 5 g/ml insulin, and 10% fetal calf serum [Larkins et al., 2006] . Cells were maintained at 37 o C in 95% air/5% CO 2 , fed every 2 days, and split 1:3 when at, or near, confluency. All human cancer cells were obtained from the ATCC.
XOR QUANTITATION
Total XOR activity was determined at 293 nm by quantitation of oxypurinol inhibitable uric acid synthesis using a Cary spectrometer, 1cm path length, and a molar extinction coefficient for uric acid of 12,600 M À1 as previously described [Seymour et al., 2006] .
SDS-PAGE AND WESTERN IMMUNOBLOT ANALYSIS
Cells to be used in immunoblot analyses were washed twice with icecold PBS, resuspended in RIPA lysis buffer (50 mM Tris-base pH 8.0, 150 mM NaCl, 1% NP-40, 0.2% SDS, 25 mM EDTA, 2 mM DTT, 10 mM NaF, and 10 mM Na 3 VO 4 ; PMSF, aprotinin, leupeptin, and pepstatin were added at 1 mM immediately prior to use), sedimented at 10,000 rpm for ten minutes at 48C, the supernatants isolated and kept on ice. Protein concentration in the supernatant was determined using the bicinchoninic acid assay (Sigma-Aldrich). Aliquots containing 50 g of protein were incubated with equal amounts of loading buffer (5% -mercaptoethanol, 95% Laemmli loading dye) for 10 min at 378, then boiled for 5 min. Samples were then separated by electrophoresis on 7.5% SDS-PAGE or 4-20% gradient SDS-PAGE gels for 40 min at 100 V, transferred to PVDF membranes (Whatman, Inc., AL). Membranes were blocked overnight at 48 in 5% non-fat dried milk in Tris-buffered saline (pH 7.6) containing 0.1% Tween. Membranes were then incubated with antibodies as indicated. Antigen-antibody complexes were detected by reaction with an ECL Western blotting detection kit according to manufacturer's instruction (Amersham Life Sciences, Piscataway, NJ). Each experiment was run in duplicate or triplicate, and representative immunoblots are shown.
HUMAN XOR UPSTREAM DNA CLONING, DELETION CONSTRUCTION, AND EXPRESSION
Upstream DNA from the human XOR genomic locus was obtained using the bacterial artificial chromosome (BAC) clone BAC26F21 (accession number AL121654; gi 6002387). DNA was prepared as described by the clone's supplier, Research Genetics. XOR upstream DNA, including the previously identified basal promoter [Xu et al., 1996 [Xu et al., , 2000 , was amplified from BAC26F21 by PCR as described previously Roberts et al., 2007] . Briefly, upstream DNA was amplified using the 5 0 primer hXDHP1 5 0 -ATCAAACTCGAGGACATTCATTGTTGTTCATTTTATTGGGGTGG-3 0 which incorporates an Xho-I cleavage site (bold) 5 0 of the XOR sequence. This was paired to the primer hXDHCON 5 0 -GAAAAC-CAATTTGTCTGCTGCCATGGTCACAGGGTGGGGTC-3 0 which introduces two nucleotide substitutions in the human XOR DNA (CAATGA) that convert the translational start site of XOR into an Nco1 site (CCATGG) and allows subsequent fusion to the translational start site of the luciferase gene in the pGL3-Basic expression vector. The resulting 1.9 kb PCR product was cloned into the TopoII vector and sequenced from both directions, generating the clone phXDPRO-1.9. The resulting sequence was identical to that for BAC26F21 and to the previously reported XOR upstream DNA [Xu et al., 1996] . DNA cloned in TopoII was excised by Xho-1 and Nco-1 cleavage and cloned into pGL3-Basic to generate the clone phXD-B1. Potential transcription factor binding sites were identified by the TESS multifactorial detection software (www.cbil.upenn.edu/ cgi-bin/tess/) and the TRANSFAC 4.0 database which confirmed the location of previously identified transcription factor binding [Xu et al., 1996] . Ten in-frame deletion fusions to the translational start site of the luciferase gene in the pGL3-Basic (pGL3-B; Promega) were constructed in steps of 200 bp as indicated previously [Clark et al., 1998a,b; Wright et al., 2000; Roberts et al., 2007] . Upstream DNA deletions to be cloned in pGL3-B were amplified by PCR using phXDPRO-1.9 as a template for PCR. Upstream primers were paired to 3 0 primer, hXDHCON. The resulting PCR products were cleaved with XhoI and Nco1 and cloned in the forward orientation in pGL3-B. The resulting deletions have been designated here by the location of each 5 0 end relative to the ''A'' (þ1) in the translational start ATG for human XOR, and the clones designated phXD-B1 to phXD-B10, corresponding to 1,900 and 200 bp of upstream DNA, respectively. A functional basal promoter was identified previously between þ1 and À200 bp and corresponds to phXD-B10. This region has been extensively characterized [Xu et al., 1996] . Luciferase fusion constructs were confirmed by DNA sequence analysis as described . All sequences were determined from both directions and sequence data were compiled manually. Oligonucleotides used as PCR or sequencing primers are available upon request.
XOR cDNA CLONING AND EXPRESSION
Full-length recombinant mouse XOR cDNA was obtained from Dr. Enrico Garattini (Mario Negri, Milan, Italy) . Coding region sequence was amplified by PCR (PCR Extender System, 5-Prime, Inc., Broomfield, CO) using the forward primer 5 0 -CATTTCCGGTCG-ACCACGAGGACAACGGTAGATGAGTTG-3 0 and the reverse primer
These primers were designed to create Sal I and Not I recognition sites, respectively (bold). The amplified sequence was cloned into the pCR2.1-TOPO vector (Invitrogen) using Sal I and Not I cleavage sites. The resulting clone was sequenced using M13 primers and the following internal forward primers: 5 0 -GTCATGAGTATGTAC-
CTTCCAGCC-3 0 , and the internal reverse primers: 5 0 -CGAGAGA-
DNA was excised from this clone with Sal I
and Not I and cloned into the pCMV-Myc expression vector (Clontech) with the same restriction enzymes. This cloning strategy fuses in frame the amino terminal coding region of XOR with the cMyc tag encoded on pCMV-Myc. Recombinant DNA was prepared from E. coli TOP10 cells (Invitrogen) according to the manufacturer's recommendations. Clones were characterized by DNA sequencing using the pCMV forward primer 5 0 -GATCCGGTACTA-GAGGAACTGAAAAAC-3 0 . The full-length clone used in the present analysis has been designated pCMV-Myc-XOR-1 and has been referred to in the present communication as pCMV-Myc-XOR.
TRANSFECTION AND LUCIFERASE REPORTER ASSAY
Cells to be transfected were grown to 70-80% of confluency in 6-well plates and shifted to 2 ml of fresh RPMI 1640 medium without serum or antibiotics one hour prior to transfection. Transfections were conducted using Lipofectamine 2000 (Invitrogen) essentially as described by the supplier. Briefly, 5.1 g of total plasmid were mixed in 0.5 ml of RPMI 1640 medium and subsequently mixed with 0.5 ml of the same medium containing 10 l of Lipofectamine 2000. After combining both solutions and mixing, the transfecting solution was held at room temperature for 20 min and then applied to cells in 1-well of a 6-well plate. Medium was removed after 4 h and replaced with standard growth medium. Cells were harvested for analysis after 48 h of incubation. Cytoplasmic extracts were analyzed for luciferase activity (Promega CCLR kit) using a BMG Lab Technologies (Durham, NC) Lumistar luminometer. As reported by others, many -galactosidase co-transfecting plasmids suppressed activity of the XOR reporter, including pRSV--galactosidase [Xu et al., 1996 [Xu et al., , 2000 . However, we observed that the co-transfecting plasmid pcDNA3.1(þ)-HisMycLacZ exerted no suppressive effect on expression from any XOR deletion fusion. Thus, all transfections included 0.1 g of pcDNA3.1(þ)-HisMycLacZ to normalize for transfection efficiency between cell lines. In addition, where plasmid titration was employed, pGEM4 was included at appropriate levels to bring the final mass of DNA to 5.1 g. -galactosidase activity was determined exactly as described previously [Norton and Coffin, 1985] . Luciferase activity was normalized to both -galactosidase units and to total cytoplasmic protein as determined spectrophotometrically using the bicinchoninic acid assay. Each individual transfection was assayed in quadruplicate, and each individual transfection was repeated six times, thus each value reported represents 24 biochemical assays for each parameter. Luciferase values represent arbitrary light units/mg protein/minute/-galactosidase unit. Means and standard deviation were calculated for each group, and in most cases standard deviations were no greater than 10% of the mean value. Comparisons between groups used ANOVA or the Student's t-test where a P-value of <0.05 was considered significant.
HC11-C4 AND HC11-C24 CLONAL SELECTION
HC11-C4 and HC11-C24 were derived from the HC11 parental strain by limiting dilution. Single colonies were isolated, expanded, and tested for the development of F-actin stress fibers following treatment with recombinant mouse TGF-1 (R&D Systems, Inc., Minneapolis, MN). F-actin was detected using phalloidin staining. Time and dose response to TGF-were optimized over a period of 0 h, 6 h, 12 h, days 1 through 9, and from 0 to 10 ng/ml of TGF, respectively. TGF was subsequently used at 5 ng/ml with F-actin stress fibers analyzed over a 48 h time course. HC11-C4 and HC11-C24 were routinely maintained in RPMI 1640 medium containing 2.05 mM L-glutamine (Gibco) supplemented with 10% fetal bovine serum (FBS), 10 ng/ml epidermal growth factor (EGF), 5 g/ml insulin, and 1Â antibiotic antimycotic supplement (Gibco). When treated with TGF-1, cells were switched to HI media (complete media containing heat inactivated FBS).
IMMUNOFLUORESCENT LABELING Six-well plates containing 22 mm diameter cell culture treated coverslips (Nunc) were seeded at 1 Â 10 5 cells/well and grown for 2 days. Cells were washed twice in ice cold PBS and fixed in 2% paraformaldehyde for 15 min. The cells were rinsed with PBS and the aldehyde quenched with 0.1 M glycine for 5 min. Cells were then incubated with Triton X-100 at 0.1% for 10 min. Non-specific protein binding was blocked with 1% BSA for 1 h. F-actin was stained with Alexa Fluor 488 phalloidin (Invitrogen) by incubating cells for 15 min in a 1:100 dilution of the label in PBS. Cells were then washed, examined by fluorescent microscopy, and photographed.
MIGRATION ASSAY AND QUANTITATION
The effect of XOR on migration of mouse and human MEC was determined as described [Steelant et al., 2002; Dumont et al., 2003; Hayot et al., 2006] except that cells were grown on 12-well plates and the monolayers wounded with a small bore plastic pipette tip. Quantitation of migration was performed by open surface area calculation as described [Hayot et al., 2006] . Briefly, cells were photographed under constant magnification, the photographs printed at 260 mm Â 175 mm, and the remaining open surface area calculated. In setting the boundaries for surface area calculation lines were drawn on the leading edge of the cells such that as many cells fell to the left of the line as fell to the right of the line, as described [Hayot et al., 2006] . In all of the experiments shown here wounding was performed in triplicate and each wound was measured at three different points along the open wound. Thus, all quantitation was determined from nine independent measurements and the mean and standard deviation of the remaining open surface area are shown in each graph. Since the data shown here represent the remaining open surface area, an increase in migration appears as a decline in the remaining open surface area.
RESULTS XOR ACTIVITY IS DECREASED IN INVASIVE MEC
The loss of XOR expression observed in clinically aggressive BC may reflect an unexpected property of the tumor, tissue handling, or a specific property of the tumor cells themselves. We examined levels of XOR activity in normal mouse (HC11), human (HB4a, MCF-10A), and cancerous (MCF-7, BT20, T47D, SBKR3, MDA-MB-231, MDA-MB-435) MEC. Consistent with clinical data derived from human mammary tumors [Linder et al., 2005] , we observed high level XOR activity in normal mouse or human MEC, but markedly decreased XOR activity in human carcinoma cells (Fig. 1A) . Similar levels of XOR activity were found in HC11, HB4a, and MCF-10A cells, while MCF-7, BT20, T47D, and SBKR3 cells exhibited levels of XOR activity that were intermediate between normal MEC and the highly aggressive MDA-MB-231 or MDA-MB-435 cells. Both XOR activity and protein level were very low in the highly invasive MDA-MB-231 human BC cell line, intermediate in MCF-7 cells, but high in HC11 and HB4a normal MEC (Fig. 1A,B) .
XOR IS POORLY ACTIVATED BY POST-CONFLUENT GROWTH IN INVASIVE MEC
XOR exhibits post-confluent growth dependent induction in the HB4a normal human MEC [Page et al., 1998 ]. We quantitated MEC XOR activity (Fig. 2) and protein level over a 72 h time course beginning from the point where cells had just reached 100% of confluence in standard growth medium. While all of the MEC studied exhibited post-confluent growth dependent induction of XOR, significant differences were also observed. Neither MCF-7 cells nor HB4a cells exhibited detectable XOR activity and very low protein levels initially (Fig. 2B,C) . On the other hand, both HC11 and MDA-MB-231 cells exhibited detectable activity ( Fig. 2A,D) and protein at the same point. Although induced by post-confluent growth in MDA-MB-231 cells, XOR activity and protein levels remained very low relative to all of the other cells studied (Fig. 2D ).
XOR ACTIVITY CAN BE STIMULATED BY NECA IN HIGHLY INVASIVE
MDA-MB-231 CELLS To determine whether the low level of XOR activity observed in MDA-MB-231 cells was the result of down-regulation per se or the result of a functionally deficient gene, we examined MDA-MB-231 cells for the capacity to induce XOR activity with n-ethylcarboxamido adenosine (NECA). NECA was previously found to be a potent inducer of XOR activity that may function through pathways known to activate XOR gene expression . As shown here (Fig. 2E ), 48 h of treatment with NECA induced XOR activity in both HC11 mouse MEC and in MDA-MB-231 cells. These data demonstrate that XOR activity can be induced in MDA-MB-231 cells and suggest that XOR expression may be down-regulated in MDA-MB-231 cells.
XOR PROMOTER ACTIVATION IS DECREASED IN INVASIVE MEC
XOR is transcriptionally regulated in several different mammalian cells, including MEC [Terada et al., 1997; Page et al., 1998; McManaman et al., 2000; Xu et al., 2000 Xu et al., , 2004 Seymour et al., 2006] . To determine if the XOR upstream regulatory DNA, including its previously characterized basal promoter [Martelin et al., 2000; Xu et al., 2000 Xu et al., , 2004 , was down-regulated in human MEC, 1,900 bp of human XOR upstream DNA was cloned and fused in-frame with the translational start of the luciferase gene in the pGL3-Basic vector. Ten step-wise deletions of the XOR upstream DNA were generated. Transfection of each of these into HC11 mouse MEC or HB4a human MEC revealed a similar pattern of activation with the Ten individual clones of the XOR deletion set, spanning the upstream region from À1,900 to À200 bp, were transfected into mouse HC11 or human HB4a MEC respectively. Expression from each deletion was determined 48 h after transfection. The parent expression vector, pGL3-Basic (pGL3-B) was transfected independently in each series. Note, the B10 designation, for example, corresponds to phXD-B10 and comprises the previously characterized XOR promoter, while B1 corresponds to phXD-B1 and comprises 1.9 kb of upstream regulatory DNA. C: The phXD-B1 clone containing 1.9 kb of XOR upstream regulatory DNA, including the proximal 200 bp promoter, was transfected into the indicated cells at 1.0-5.0 g of DNA. Cells were co-transfected with 0.1 g of pcDNA3.1(þ)HisMycLacZ and sufficient amounts of pGEM4 to bring the total mass of DNA to 5.1 g. Cells were harvested after 48 h, and luciferase expression and lacZ expression were determined. Data were normalized to the amount of lacZ expression and are shown as normalized relative light units (RLU).
exception that the phXD-B10 DNA showed reduced expression in human MEC that was not observed in mouse MEC (Fig. 3A,B) . Since phXD-B1 was comparably activated in both mouse and human cells, we transfected phXD-B1 into HC11 mouse MEC and into the human MECs HB4a, MCF-7, and MDA-MB-231 over a DNA titration range of 1, 2, 3, 4, and 5 g. While each cell showed increased luciferase expression with increasing DNA used in transfection (Fig. 3C) , for each level of DNA used in transfection expression of the XOR upstream DNA was reduced in human cancer cells relative to that obtained in normal mouse or human MEC, in parallel with the data observed for XOR activity and protein level. These data confirm that XOR promoter activation is decreased in MCF-7 and MDA-MB-231 human mammary cancer cells.
XOR ACTIVITY AND PROTEIN LEVEL ARE DECREASED IN CLONALLY SELECTED HC11 CELLS WITH HIGH MIGRATORY ACTIVITY
Our unpublished experiments had demonstrated that HC11 mouse MEC were heterogeneous with respect to their response to TGF stimulation and suggested that migratory activity in response to TGF may also be heterogeneous in HC11 cells as well. Single colonies were isolated from serially diluted cultures of HC11 and examined for the development of F-actin stress fibers in response to TGF. Two clones were isolated that differed dramatically in response to TGF, HC11-C4 and HC11-C24. HC11-C24 cells exhibited extensive Factin stress fiber development after exposure to TGF whereas HC11-C4 exhibited markedly reduced response to TGF (Fig. 4A) . We observed marked reduction in expression of -smooth muscle actin (-SMA) in response to TGF stimulation (Fig. 4B ,C) when cells were examined over an extended time course. While both cells induced -SMA transiently, and at the same point in time, HC11-C4 expressed approximately sixfold less -SMA expression at all time points. We tested HC11-C4 and HC11-C24 for migratory activity using a wounding assay in the presence or absence of TGF. Cells were examined 0, 19, and 31 h after wounding and the addition of TGF. We observed that HC11-C24 showed extensive migration 31 h after wounding whereas HC11-C4 exhibited markedly reduced migration in response to TGF-throughout the 31 h time course (Fig. 4D,E) . Significantly, HC11-C24 showed more extensive migration than HC-11-C4 even in the absence of TGF stimulation (Fig. 4D,E) . In parallel with the results obtained with the highly invasive human MDA-MB-231 cells, XOR activity and protein level in HC11-C24 were markedly reduced in contrast to HC11-C4 (Fig. 4F,G) . A summary of several different characteristics of HC11-C4 and HC11-C24 is shown in Table I . These data demonstrate that the reduced XOR activity and protein levels observed in the highly invasive MDA-MB-231 cells was paralleled in clonally selected HC11-C24 mouse MEC that also exhibit a high level of migratory activity in vitro.
OVER-EXPRESSION OF XOR cDNA INHIBITS MIGRATORY ACTIVITY OF HC11-C24 AND MDA-MB-231 CELLS
Recombinant mouse XOR cDNA was cloned into the expression vector pCMV-Myc to create pCMV-Myc-XOR which was transfected into both HC11-C24 and MDA-MB-231 cells at different input doses of DNA. XOR activity was determined 24 h later, and both mouse and human cells exhibited functional over-expression of the cDNA (Fig. 5A,B) . Expression of Myc-tagged XOR in MDA-MB-231 was confirmed by Western immunoblot against the Myc tag (Fig. 5C ). HC11-C24 cells were transfected with pCMV-Myc-XOR or the empty vector in the presence or absence of the XOR specific inhibitor Y- Fig. 4 . Clonally selected HC11-C24 cells exhibit high migration and reduced XOR expression. A: HC11-C4 and HC11-C24 cells were grown on glass coverslips to 80% confluency, treated with TGF, and 24 h later were stained with Alexa Fluor 488 phalloidin, and photographed. B,C: HC11-C4 and HC11-C24 cells were grown as indicated above. Cells were then treated as described in the lane designation below, lysed in RIPA buffer, and Western blots performed (C) against -SMA or -Actin and quantitated by scanning dosimetry (B). Lane 1, 1 day of growth without TGF; lane 2, 9 days of growth without TGF; lane 3, 6 h growth after 5ng/ml TGF-1; lane 4, 12 h after TGF1; lane 5, 1 day after TGF-1; lane 6, 2 days after TGF-1; lane 7, 3 days after TGF-1; lane 8, 9 days after TGF-1; lane 9, 12 h without TGF. Band intensity was quantitated using Kodak Imager software, and relative intensities normalized to the signal obtained with -Actin (B). D,E: HC11-C4 and HC11-C24 were grown to confluency, wounded with a plastic pipette tip, and washed three times in PBS to remove floating cells. Medium was then replaced with standard growth medium containing 10% heat inactivated FCS, and 5.0 ng/ml TGF was added or not as indicated. Cells were photographed at 0, 19, and 31 h after the addition of TGF. Migration was quantitated by open surface area calculation (D), and representative photomicrographs are shown for each time point (E). F: HC11-C4 and HC11-C24 were grown to confluency in 6-well plates, cells were harvested 3 days later, and XOR activity was determined. Data show the mean and standard deviation of six determinations. G: Western immunoblot analysis was performed on the whole cell extracts used in panel F, and three representative lanes are shown for both cell types. 700. After 24 h, when the cells had reached confluency, they were subjected to wounding, quantitated, and representative photomicrographs obtained 0, 19, and 31 h after wounding. Transfection with pCMV-Myc-XOR, but not the empty vector, inhibited HC11-C24 migratory activity, and this effect was reversed by co-treatment with Y-700 (Fig. 5D,E) . MDA-MB-231 cells were also transfected with pCMV-Myc-XOR or the empty vector in the presence or absence of Y-700 and the effect on wound induced migratory activity determined. As observed for HC11-C24 cells, MDA-MB-231 migratory activity was inhibited by over-expression of pCMV-Myc-XOR but not the empty vector (Fig. 5F,G) . As observed with HC11-C24, co-treatment with Y-700 reversed the effect of pCMV-Myc-XOR on migratory activity. Thus, MEC of both mouse and human origin that exhibited markedly reduced XOR expression and a high degree of migratory activity showed reduced migration when induced to overexpress XOR by transfection of recombinant XOR cDNA, and this effect was reversed by the XOR specific inhibitor Y-700.
PHARMACOLOGICAL INHIBITION OF XOR STIMULATES MIGRATION IN HC11-C4 AND MCF-7 CELLS
HC11-C4 mouse or MCF-7 human MEC were grown to confluency and treated with either oxypurinol (150 M), allopurinol (150 M), Y-700 (1 M), or remained untreated. After one hour, cells were subjected to wounding, washed, and the medium refreshed in the presence of XOR inhibitors. The time course of migration was monitored in the absence of TGF stimulation. As shown in Selected characteristics of HC11-C4 and HC11-C24 cells are shown. *, spontaneous cell death rate was determined after growing cells in standard rich medium containing 10% FCS and then shifting the cells into serum free medium (SFM). Cells were grown for 48 h following the shift into SFM and spontaneous cell death was determined following trypsinization and washing using Trypan Blue exclusion and manual counting with a hemocytometer. #, doubling time for each cell line was determined by plating at a density of 3.0 Â 10 5 cells per well in 6-well trays. Trypsinized cells were counted manually 24 and 48 h later using a hemocytometer. Response to TGF was determined by Western immunoblot (-SMA, E-cadherin) as shown above or by visual inspection of photomicrographs (phalloid stain for F-actin fiber formation). XOR activity was determined as shown in Figure 4F . Figure 6A ,B, all three XOR inhibitors quantitatively stimulated migration in HC11-C4 cells that was readily apparent 19 h after wounding and was further stimulated 31 h after wounding. Similar results were obtained for MCF-7 cells that were more marked 48 h after wounding (Fig. 6C,D) .
XOR DERIVED ROS MAY CONTRIBUTE TO SUPPRESSION OF MEC MIGRATION
HC11-C4 and MDA-MB-231 MEC, but not HC11-C24, both showed dose dependent activation of XOR by NECA (Fig. 7A) . Accordingly, we exposed HC11-C4 and MDA-MB-231 to NECA over abroad concentration range in the absence or presence of either Y-700 or the ROS scavenger NAC. Cells were subjected to wounding which was quantitated 19 h (HC11-C4) or 48 h (MDA-MB-231) later. HC11-C4 exhibited a modest reduction in migratory rate by NECA treatment that was reversed by both Y-700 and NAC (Fig. 7B) . MDA-MB-231 exhibited marked reduction in migratory rate by NECA which was also reversed by both Y-700 and NAC (Fig. 7C) . To determine whether ROS scavenging in the absence of NECA would also affect MEC migratory rate, HC11-C4 and MDA-MB-231 were treated with NAC in the absence of NECA and migratory rate after wounding was determined. Both cells exhibited NAC dose dependent increase in migratory rate (Fig. 7D,E) . The same experiment was performed in the presence of a broad concentration range of urate, a well-recognized scavenger of both hydroxyl radical and peroxynitrite. Both HC11-C4 and MDA-MB-231 MEC exhibited urate dose dependent increase in migratory rate (Fig. 7F,G) .
XOR MODULATES COX-2 EXPRESSION IN CARCINOMA AND NORMAL MEC
COX-2 may comprise a significant source of ROS in carcinoma and normal MEC [Smith et al., 2000] , and its expression has been linked to invasiveness in vivo and migratory activity in vitro [Singh et al., 2005; Larkins et al., 2006] . We observed low or even decreasing expression of COX-2 with growth in MEC showing high XOR activity and weak migratory activity in vitro including HC11-C4, MCF-7, and HB4a (Fig. 8A) . In contrast, HC11-C24 and MDA-MB-231 that exhibit low XOR activity and high migratory activity in vitro also exhibited high, growth induced levels of COX-2 (Fig. 8A) . It was reported that heterozygous knockout of XOR in the germline revealed XOR to be an endogenous regulator of COX-2 in mouse fibroblasts, although these experiments did not report regulation in MEC [Ohtsubo et al., 2004] . Accordingly, we transfected the high COX-2 expressing HC11-C24 and MDA-MB-231 cells with pCMVMyc-XOR or the control vector pCMV-Myc and examined COX-2 protein levels 48 h later. We observed that forced ectopic overexpression of XOR reduced COX-2 expression in both cells (Fig. 8B) . Conversely, treatment of HC11 and MCF-7 cells exhibiting high XOR and weak COX-2 protein levels with either oxypurinol or allopurinol resulted in increased levels of COX-2 protein (Fig. 8C) . These data indicate that XOR also modulates COX-2 protein levels in both mouse and human MEC, and they suggest a potential mechanism by which XOR and COX-2 jointly contribute to migratory activity in vitro.
XOR MODULATES MMP1 AND MMP3 LEVELS AND FUNCTION IN CARCINOMA MEC
Matrix metalloproteases play key roles in tumor metastasis, invasiveness, and MEC in vitro migratory activity [Brinckerhoff et al., 2000; Pei, 2005] . MMP1 and MMP3 specifically have been associated with increased MEC migratory activity in vitro [Davies et al., 1993; Wiesen and Werb, 1996; Pei, 2005] . We examined the effect of XOR inhibition on levels of MMP1 and MMP3 in MDA-MB-231 cells that had been cultured for 72 h after reaching confluence where XOR exhibited low but significant induction. Both oxypurinol and Y-700 treatment increased levels of MMP1 and MMP3 (Fig. 9A ) consistent with the increased migratory activity observed following Y-700 treatment of these cells. Treatment of MDA-MB-231 with NECA for 24 h reduced expression of both COX-2 and MMP1, and Y-700 or NAC pretreatment blocked the decrease in COX-2 or MMP1 protein levels observed (Fig. 9B) . To determine whether the suppressive role of XOR on MMP protein level was indeed reflected in the migratory activity of human carcinoma cells, we determine the effect of Y-700 in the presence or absence of MMP inhibitors I and III. We selected BT20 human mammary carcinoma cells for these analyses since they exhibited good but still intermediate levels of XOR activity (Fig. 1A) . As shown in Figure 9C ,D, Y-700 alone stimulated BT20 migratory activity, and this effect was reversed by co-treatment with MMP inhibitors I and III. These data suggest that the suppressive role played by XOR on migratory activity in vitro may be mediated in part by reduction of COX-2 and MMP protein levels.
DISCUSSION
Clinical observations have suggested the possibility that downregulation of XOR may be functionally linked to aggressive BC and BC recurrence. Consistent with these observations, data shown here revealed high levels of XOR activity and protein in normal mouse or human MEC that was reduced or markedly reduced in weakly or highly invasive human tumor cells, respectively. Investigation of the role of XOR expression on migration in vitro demonstrated that over-expression of recombinant XOR cDNA in the highly invasive MDA-MB-231 and in HC11-C24 cells that exhibit low XOR activity and protein levels inhibited migratory activity of both cells in vitro. Conversely, pharmacological inhibition of XOR in MCF-7 and HC11-C4 MEC that possess high levels of XOR activity and protein induced their migration in vitro. These data have revealed a functional link between XOR expression and the migration of MEC and suggest a potential role for the loss of XOR and the poor prognosis of BC patients expressing little or no XOR [Linder et al., 2005] . Data shown here have, for the first time, demonstrated that XOR activity, protein level, and promoter activation are decreased in human tumor derived MEC that exhibit highly invasive phenotype both in vitro and in vivo. MDA-MB-231 cells exhibit both high migratory activity in vitro [Larkins et al., 2006] and are highly invasive in mouse xenograft models in vivo Li et al., 2007] . Importantly, MDA-MB-231 cells poorly expressed XOR and exhibited weak XOR promoter activation. That MDA-MB-231 cells exhibited strong XOR activation by NECA suggests that XOR was down-regulated in these cells and not functionally impaired. Our data also demonstrated that over-expression of recombinant XOR cDNA in MDA-MB-231 cells greatly reduced their migratory activity in vitro, and this identified a potential functional role for XOR in suppressing migratory activity. Similar observations were made in the clonally selected mouse MEC, HC11-C24. The HC11-C24 line was found to possess both low XOR activity and protein levels and high migratory activity in vitro, and over-expression of XOR cDNA in these cells also suppressed migratory activity. Thus, the capacity for XOR to suppress in vitro migration was independent of the species from which the MEC were derived, and it arose in cells with weak endogenous XOR expression.
The involvement of XOR in suppressing MEC migration was confirmed in the converse fashion using MCF-7 cells and the clonally selected HC11-C4 cells. MCF-7 cells exhibited intermediate levels of XOR activity, protein levels, and promoter activation that was higher than MDA-MB-231 but lower than HB4a normal human MEC. MCF-7 cells are weakly invasive in vivo [Aharinejad et al., 2004; Li et al., 2006] and exhibited weak migratory activity in the present in vitro experiments. Migratory activity of MCF-7 cells was significantly accelerated by three different XOR inhibitors: allopurinol, oxypurinol, and Y-700. The use of these different inhibitors is important because they possess very different capacity to scavenge ROS, and recent reports suggest that Y-700 may have no ROS scavenging capacity [Fukunari et al., 2004] . Furthermore, Y-700 exhibits very strong non-competitive inhibition of XOR with a reported Ki of only 0.6 nM [Fukunari et al., 2004] . Together, the three inhibitors unambiguously identify the contribution of XOR. Again, and in parallel with the previous experiments, the clonally selected HC11-C4 cell line provided further support for the contribution of XOR. HC11-C4 cells exhibited high levels of XOR activity and protein and weak migratory activity in vitro that was markedly accelerated by all three inhibitors. Thus, the contribution While the mechanism by which XOR inhibits migratory activity is unknown, the capacity for XOR to contribute to functional differentiation [Kurosaki et al., 1996; Linder et al., 1999; McManaman et al., 1999 McManaman et al., , 2000 McManaman et al., , 2002 Seymour et al., 2006; Anderson et al., 2007] could in principal inhibit tumorigenesis or invasiveness, and by implication migration in vitro. However, as a source of intracellular ROS, RNS, or uric acid XOR may regulate many aspects of MEC function or signaling that could also modulate migratory activity. Stimulation of XOR activity with NECA reduced migratory rate in both HC11-C4 and MDA-MB-231 cells, and the XOR inhibitor Y-700 blocked NECA mediated inhibition of migration in both cell types. The involvement of ROS in the NECA response was demonstrated by co-treatment with N-acetylcysteine which resulted in marked increase in migratory activity of both cell types. When the effect of ROS scavenging was tested in the absence of NECA activation an apparent paradox was uncovered. We tested the independent effects of NAC, a scavenger of hypochlorous acid (HOCl), hydroxyl radical, and H2O2 [Aruoma et al., 1989] , and urate, a scavenger of both peroxynitrite and hydroxyl radical. Both HC11-C4 (high XOR) and MDA-MB-231 (low XOR), showed markedly increased migratory activity in response to both NAC and urate. These data are readily reconciled for HC11-C4 by the high endogenous expression of XOR. The levels of urate used in these experiments (1.6-25 mg/dl) are commonly used in studies of ROS scavenging, however, it may be equally important that urate can also act to feedback inhibit XOR [Tan et al., 1993] , and this may Fig. 8 . XOR contributes to COX-2 regulation in carcinoma and normal MEC. A: The indicated MEC were grown to confluence and harvested every 24 h over the subsequent 72 h. Whole cell extracts were prepared and used for Western blot analysis of COX-2 and -Actin, which was used to standardize loading of the gels. All samples were run in triplicate, and representative blots are shown for each. B: HC11-C24 and MDA-MB-231 were transfected in 6-well plates with 4.0 g of either pCMV-Myc vector (lanes 1 and 2) or pCMV-Myc-XOR (lanes 3 and 4). Whole cell extracts were prepared 48 hours after transfection and Western blots were analyzed for COX-2 expression and -Actin. Duplicate samples were analyzed for each, and XOR protein levels were quantitated by scanning dosimetry and normalized to the -Actin signal. C: HC11 and MCF-7 cells were plated in 6-well plates at 35% confluency. After 24 h cells were treated with either oxypurinol or allopurinol at 150 M. Whole cell extracts were prepared 24 h later and analyzed for expression of COX-2 and -Actin. Band intensity was quantitated by scanning dosimetry. Samples were prepared in triplicate and representative blots are shown.
contribute to the effects of urate on HC11-C4 migratory activity. In the case of MDA-MB-231 cells, however, the independent effects of NAC and urate suggest the presence of an additional source of ROS whose scavenging further increases migratory activity. It is paradoxical, then, that activation of XOR in MDA-MB-231 by NECA reduced migratory activity-an effect reversed by the XOR specific inhibitor Y-700. We imagine that activation of XOR in MDA-MB-231 cells may alter the global redox balance of the cells which then inhibits migratory activity. The complex reactions in which XOR may participate, including synthesis of urate, superoxide, or nitric oxide suggests many ways in which XOR could affect global redox balance, and further experiments will be needed to clarify this effect on migratory activity. Previous reports demonstrated the key role of XOR in modulating COX-2 expression in mouse fibroblasts [Ohtsubo et al., 2004] . COX-2 is well-recognized to promote tumorigenesis, metastasis, and migration [Liu et al., 2001; Lu et al., 2005; Singh et al., 2005] , whereas its knockout or inhibition decreases tumorigenesis, migration, and invasiveness of mammary cancer cells [Howe et al., 2005; Larkins et al., 2006] . Our experiments uncovered a generally converse relation between XOR and COX-2. MEC exhibiting strong growth dependent expression of XOR (HC11-C4, HB4a, MCF-7) exhibited weak or declining COX-2 expression, while MEC exhibiting weak XOR expression showed high levels COX-2. Ectopic over-expression of XOR in these cells resulted in decreased COX-2 levels, and conversely inhibition of XOR in cells with strong expression increased levels of COX-2. Thus, XOR appears to modulate COX-2 protein levels in MEC of mouse or human origin. It is, however, important to note that expression of XOR does not preclude absolutely expression of COX-2. For example, in MDA-MB-231 cells COX-2 is vigorously induced by growth whereas XOR shows weak but positive induction at the same time. Nonetheless, over-expression of XOR both suppressed migratory activity in vitro and COX-2 protein levels.
The mechanisms underlying the converse, growth-dependent regulation of XOR and COX-2 are not understood. Growthdependent effects on several aspects of MEC physiology, including XOR expression, have been studied [Page et al., 1998; Fang et al., 2007] . While growth-dependent transcriptional affects on XOR have been identified, the basis for these effects is also poorly understood. It was postulated that growth dependent resistance to antineoplastic drugs in MDA-MB-231 reflects contributions of both HIF-1 and unknown factors released by the cells [Fang et al., 2007] . We imagine that the forced ectopic over-expression of XOR could shift the intracellular redox balance in MEC and thereby modulate COX-2 expression. COX-2 appears to play a critical role in both migratory activity of mammary tumor cells [Rozic et al., 2001] and in promoting the survival of tumor cells [Teh et al., 2004; LanzaJacoby et al., 2006] , and its modulation by XOR may both suppress migratory activity and compromise survival. 2 and H 2 O 2 during catalysis. NO can be generated directly from XOR catalysis during nitrite metabolism, contributing to RNS generation. Urate will be formed by XOR following xanthine oxidation. We posit that XOR derived ROS, RNS, or urate may contribute to modulation of COX-2. When COX-2 levels are sufficiently high, it is imagined that COX-2, possibly through and ROS based mechanism, stimulates MMP1/MMP3 levels contributing to migratory activity. Modulation of COX-2 by high level XOR activity is then imagined to reduce MMP1/MMP3 and migratory activity. AA, arachidonic acid; PGE, prostaglandin; NAC, N-acetylcysteine.
We observed a similar inverse relationship between XOR and levels of MMP1 and MMP3, and inhibition of XOR increased levels of both proteins in human carcinoma cells. MMPs are wellrecognized and important mediators of tumor cell migratory activity in vitro [Davies et al., 1993; Wiesen and Werb, 1996; Pei, 2005] , and the increased levels of both MMP proteins observed by inhibition of XOR suggests that XOR suppresses either their maturation or protein expression. We postulated that if XOR suppressed MMP1 and MMP3, and MMPs were important mediators of carcinoma migratory activity in vitro, then inhibiting XOR with Y-700 would release MMPs from the inhibitory action of XOR and stimulate migratory activity. Furthermore, selective inhibition of MMP function in cells already inhibited for XOR activity should decrease migratory activity. We observed exactly this behavior in the human BT20 carcinoma cell line using two different MMP inhibitors. These data, therefore, provide strong corroborative evidence for the role of XOR in decreasing in vitro migratory activity, a process mediated in part by the suppressive effect of XOR on MMP1 and MMP3 protein levels and function.
Our data suggest a mechanism that is consistent with both the observed effects on migratory activity in vitro, XOR and COX-2 expression, and recent clinical observations (Fig. 10) . We imagine that in cells showing high XOR expression (Fig. 10) that it, and additional but unknown factors, contribute to modulation of COX-2 and the subsequent down regulation of COX-2 derived ROS, leading to dampening of MMP expression, migratory activity, and an improved clinical outcome. COX-2 is well known to generate superoxide which can be reduced to hydrogen peroxide, a potential mediator of MMP expression [Zhang et al., 2002] that stimulates tumor progression and migratory activity [Storz, 2005; Wu, 2006] . In the converse situation, where COX-2 is highly expressed and XOR poorly expressed, COX-2 may contribute significantly to MMP expression, migratory activity, and poor clinical outcome. NAC and urate may stimulate migratory activity in vitro as scavengers of ROS/RNS derived from other unknown sources and perhaps in part from XOR. The capacity for XOR to reduce levels of COX-2, MMPs, and migratory activity has great significance for modulating the course of BC progression and metastasis. Identifying the mechanisms that underlie this process may offer unique opportunities for chemoprevention or novel intervention not previously investigated for BC.
